SRPT Sarepta Therapeutics, Inc.

34.72
0  0%
Previous Close 34.86
Open 35.10
Price To book 5.67
Market Cap 1.90B
Shares 54,813,000
Volume 2,814,516
Short Ratio 3.81
Av. Daily Volume 2,205,000

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Approved September 19, 2016.
Eteplirsen
Duchenne muscular dystrophy

Latest News

  1. Edited Transcript of SRPT earnings conference call or presentation 27-Apr-17 8:30pm GMT
  2. Sarepta Pops On Consensus-Topping Revenue, Boosts 2017 Guide
  3. Sarepta Tests Biotech's CEO Vacuum Hypothesis
  4. ​Sarepta shares jump as CEO’s planned exit spurs takeover speculation
  5. Sarepta (SRPT) Q1 Loss Narrows, Exondys 51 Sales Pick Up
  6. Yes, Sarepta Reported Earnings…But That's Not Why It's Flying Today
  7. Biotech Movers: CEO Exit, Tea Leaf Reading Prompts Surge in Sarepta Shares
  8. Sarepta CEO Exits Along With a Sanofi Director, So Let's Speculate About a Possible Deal
  9. Sarepta Therapeutics tops Street 1Q forecasts
  10. Sarepta Therapeutics Announces First Quarter 2017 Financial Results and Recent Corporate Developments
  11. Investor Network: Sarepta Therapeutics, Inc. to Host Earnings Call
  12. Sarepta: A Victim of High Expectations?
  13. Is the Options Market Predicting a Spike in Sarepta (SRPT) Stock?
  14. 5 Earnings Short-Squeeze Plays: Twitter, Sarepta Therapeutics Included
  15. Sarepta Pops on Bullish Sentiment Around Duchenne Therapy, PDL Up on Merck Deal: Biotech Movers
  16. Barron's Picks And Pans: Bank Stocks, O'Reilly Automotive, Sarepta And More
  17. ($$) Drugmaker Sarepta's Stock Could Double
  18. Sarepta Therapeutics, Inc. – Value Analysis (NASDAQ:SRPT) : April 19, 2017
  19. Scott+Scott, Attorneys at Law, LLP Reminds Investors of its Investigation of Sarepta Therapeutics, Inc. (SRPT)
  20. Sarepta Therapeutics, Inc. breached its 50 day moving average in a Bullish Manner : SRPT-US : April 18, 2017